biostudies-literatureUnknown6(6)Maffioli MRuxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, response criteria able to predict OS in RUX-treated patients are lacking, leading to uncertainty regarding the switch to second-line treatments. In this study, we investigated predictors of survival collected after 6 months of RUX in 209 MF patients participating in the real-world ambispective observational RUXOREL-MF study (NCT03959371). Multivariable analysis identified the following risk factors: (1) RUX dose <20 mg twice daily at baseline, months 3 and 6 (hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.07-3.00; P = .03), (2) palpable spleen length reduction from baseline ≤30% atBlood advances1855-1864https://www.ebi.ac.uk/biostudies/studies/S-EPMC8941454biostudies-literatureA prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.PMC8941454Guidetti AIurlo ACaberlon SCaramella MUbezio MKomrokji RCarraro MCMora BPolverelli NDella Porta MGLunghi FGiorgino TBertu LD'Adda MMaffioli MSissa CRumi EVismara AAnghilieri MKuykendall AFinazzi MCPassamonti FMolteni ABall SCattaneo DBrociner MElli EMfalseA prognostic model to predict survival after 6 months of ruxolitinib in patients with myelofibrosis.Ruxolitinib (RUX) is extensively used in myelofibrosis (MF). Despite its early efficacy, most patients lose response over time and, after discontinuation, have a worse overall survival (OS). Currently, response criteria able to predict OS in RUX-treated patients are lacking, leading to uncertainty regarding the switch to second-line treatments. In this study, we investigated predictors of survival collected after 6 months of RUX in 209 MF patients participating in the real-world ambispective observational RUXOREL-MF study (NCT03959371). Multivariable analysis identified the following risk factors: (1) RUX dose <20 mg twice daily at baseline, months 3 and 6 (hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.07-3.00; P = .03), (2) palpable spleen length reduction from baseline ≤30% at2022-01-01T00:00:00Z2022 Mar2026-05-09T19:51:35.433Z2025-04-05T09:57:56.164ZS-EPMC89414543513033910.1182/bloodadvances.2021006889